abstract |
The use of radiopharmaceuticals of formula (I) for the diagnosis of Alzheimer's disease is described. In particular, pharmaceuticals that are able to cross the blood-brain barrier and bind the CCR1 receptor present in the brain tissues of patients suffering from Alzheimer's disease are described. |